Hemostasis Today

May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Gayatri Digambar: Safe Anticoagulation Conversion
Dec 19, 2025, 12:13

Gayatri Digambar: Safe Anticoagulation Conversion

Gayatri Digambar, B.Pharm Finalist and Registered Pharmacist, posted on LinkedIn:

”Anticoagulation Conversion

Mastering the Transition: Ensuring Patient Safety in Complex Drug Therapy

As Registered Pharmacists, managing anticoagulation therapy transitions (bridging) is one of our most critical clinical responsibilities. The precision of these conversions directly impacts patient outcomes and minimizes the risk of bleeding or clotting.

Sharing a look at the key protocols for safely converting between different anticoagulants:

Bridging from Heparin/LMWH to Warfarin: This requires a careful overlap period until the INR is consistently in the therapeutic range (>2 for at least 2 days).

Transitioning to DOACs (Dabigatran, Rivaroxaban, Apixaban): Exact timing is crucial. For instance, stop IV heparin immediately and start the DOAC within 0–2 hours of the next scheduled LMWH dose to maintain anticoagulation continuity.

Warfarin Management: When switching from warfarin to a DOAC, the INR must be checked and confirmed to be <2 before initiating the new agent.

This attention to detail is vital for clinical excellence and regulatory compliance.”

Anticoagulation

Stay updated with Hemostasis Today.